RYTM · Rhythm Pharmaceuticals, Inc.
Market Cap
$7.38B
Shares
68.85M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$106.13
Open$106.01
Day$103.98–108.85
52W close$75.82–117.62
Avg vol 30d632K
Short int10.2M · 14.7% float · 12.2d
Short vol51%
Last earningsAug 4, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
−3%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
73%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
+14%
trailing
YTD return
−1%
this year
Relative strength
+1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $110 › 200d $99 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +63 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.75% of float · ▲ +7.6% MoM · 12.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
304 holders — near 3-yr high, broad support
Squeeze score
83
high risk · 0–100
Fundamentals
EPS growth
+28%
Y/Y
Free cash flow
$-116.6M
Quant / Vol
risk profile
Volatility
47%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
73%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $110 › 200d $99 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +63 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.75% of float · ▲ +7.6% MoM · 12.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
304 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $76
Now $106 · 73%
Range high $118
vs 200-day avg +7%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RYTM
this stock
Rhythm Pharmaceuticals, Inc.
|
$7.38B | -0.9% | +45.8% | — | 14.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RYTM | -4.8% | +3.3% | +14.1% | +6.9% | -0.9% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -5.2% | +2.0% | +0.8% | +4.3% | -13.3% |
Key facts
CIK
1649904
CUSIP
76243J105
13F (30d)
258 filings
255 filers
Visit website
Investor relations